Underweight patients
Conditions
Interventions
Underweight group:Patients were first administered 0.4 µg/kg of sufentanil. The study was conducted using the Dixon modified sequential method. The initial dose of remimazolam was 0.2 mg/kg, with a do
if the previous patient exhibited a positive response, the remimazolam dose for the next patient was decreased by 0.02 mg/kg.
Normal weight group:Patients were first administered 0.4 µg/kg of sufentanil. The study was conducted using the Dixon modified sequential method. The initial dose of remimazolam was 0.2 mg/kg, with a
Sponsors
Affiliated Hospital of North Sichuan Medical College
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Patients with low body weight (BMI < 18.5 kg/m^2) and patients with normal body weight (18.5 <= BMI < 24.0 kg/m^2); 2. American Society of Anesthesiologists (ASA) physical status I to III; 3. Aged 18 to 65 years; 4. Individuals who understand and voluntarily participate in the study and have signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1.severe cardiopulmonary diseases; 2.uncontrolled hypertension (systolic blood pressure >180 mmHg or diastolic blood pressure >110 mmHg); 3.severe hepatic or renal diseases; 4. participation in other drug clinical trials as a subject within the past 3 months; 5. severe psychiatric or psychological disorders; 6.pregnant or lactating women;7.allergy to any of the study medications.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The median effective dose (ED50) of remimazolam;The 95% effective dose (ED95) of remimazolam; | — |
Secondary
| Measure | Time frame |
|---|---|
| Mean Arterial Pressure, MAP;Heart Rate, HR;Time to loss of consciousness;sufentanil dosage during the test;remimazolam dosage during the test;propofol dosage during the test;rocuronium dosage during the test; | — |
Countries
China
Contacts
Public ContactTu Faping
Department of Anesthesiology, Affiliated Hospital of North Sichuan Medical College
Outcome results
None listed